DWTX
Dogwood Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Dogwood Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Dogwood Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Dogwood Therapeutics, Inc..
Annual filing, covered
10-K parsed · Mar 18 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 18 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Dogwood Therapeutics Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and Virios Therapeutics, Inc. The company changed its name to Dogwood Therapeutics Inc. in 2024. Dogwood Therapeutics Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Dogwood Therapeutics Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and Virios Therapeutics, Inc. The company changed its name to Dogwood Therapeutics Inc. in 2024. Dogwood Therapeutics Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Dogwood Therapeutics, Inc.
1.30
pre 1.26 +3.22%
—
—
| Manager | Value | % base | |
|---|---|---|---|
| Armistice Capital | $5.0M | 81.81% | −4.50% |
| Millennium | $550,321 | 8.93% | new |
| Vanguardindex-like | $212,768 | 3.45% | 0.00% |
| Geodeindex-like | $142,161 | 2.31% | +11.16% |
| Vanguard Fiduciary Trustindex-like | $101,005 | 1.64% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Armistice Capital | $5.0M | 81.81% | −4.50% |
| Millennium | $550,321 | 8.93% | new |
| Vanguardindex-like | $212,768 | 3.45% | 0.00% |
| Geodeindex-like | $142,161 | 2.31% | +11.16% |
| Vanguard Fiduciary Trustindex-like | $101,005 | 1.64% | 0.00% |
−3.35%
shares held · 10 largest managers
Expected move
No implied move.
Largest filed tie
—
Tall tick = annual report · Source: EDGAR
Bull2
Bear1